-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Is there a future for FabI inhibitors as antibacterial agents?
AW Karchmer, B Hafkin
Editorial: Clinical Investigation
-
Is there a future for FabI inhibitors as antibacterial agents?
AW Karchmer, B Hafkin
Editorial: Clinical Investigation
-
Is there a future for FabI inhibitors as antibacterial agents?
AW Karchmer, B Hafkin
Editorial: Clinical Investigation
-
Is there a future for FabI inhibitors as antibacterial agents?
AW Karchmer, B Hafkin
Editorial: Clinical Investigation
-
Is there a future for FabI inhibitors as antibacterial agents?
AW Karchmer, B Hafkin
Editorial: Clinical Investigation
-
Is there a future for FabI inhibitors as antibacterial agents?
AW Karchmer, B Hafkin
Editorial: Clinical Investigation
-
Is there a future for FabI inhibitors as antibacterial agents?
AW Karchmer, B Hafkin
Editorial: Clinical Investigation
-
Is there a future for FabI inhibitors as antibacterial agents?
AW Karchmer, B Hafkin
Editorial: Clinical Investigation
-
Study suggests that socioeconomic status may affect clinical trial participation
Unger JM, Hershman DL, Albain KS
News and Views: Clinical Investigation
-
Study suggests that socioeconomic status may affect clinical trial participation
Unger JM, Hershman DL, Albain KS
News and Views: Clinical Investigation
-
Study suggests that socioeconomic status may affect clinical trial participation
Unger JM, Hershman DL, Albain KS
News and Views: Clinical Investigation
-
Study suggests that socioeconomic status may affect clinical trial participation
Unger JM, Hershman DL, Albain KS
News and Views: Clinical Investigation
-
Study suggests that socioeconomic status may affect clinical trial participation
Unger JM, Hershman DL, Albain KS
News and Views: Clinical Investigation
-
Study suggests that socioeconomic status may affect clinical trial participation
Unger JM, Hershman DL, Albain KS
News and Views: Clinical Investigation
-
Study suggests that socioeconomic status may affect clinical trial participation
Unger JM, Hershman DL, Albain KS
News and Views: Clinical Investigation
-
Study suggests that socioeconomic status may affect clinical trial participation
Unger JM, Hershman DL, Albain KS
News and Views: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
Novel clinical trials in neuro-oncology
Aaron G Mammoser, David E Blas-Boria1 & Mark R Gilbert
Review Article: Clinical Investigation
-
Novel clinical trials in neuro-oncology
Aaron G Mammoser, David E Blas-Boria1 & Mark R Gilbert
Review Article: Clinical Investigation
-
Novel clinical trials in neuro-oncology
Aaron G Mammoser, David E Blas-Boria1 & Mark R Gilbert
Review Article: Clinical Investigation
-
Novel clinical trials in neuro-oncology
Aaron G Mammoser, David E Blas-Boria1 & Mark R Gilbert
Review Article: Clinical Investigation
-
Novel clinical trials in neuro-oncology
Aaron G Mammoser, David E Blas-Boria1 & Mark R Gilbert
Review Article: Clinical Investigation
-
Novel clinical trials in neuro-oncology
Aaron G Mammoser, David E Blas-Boria1 & Mark R Gilbert
Review Article: Clinical Investigation
-
Novel clinical trials in neuro-oncology
Aaron G Mammoser, David E Blas-Boria1 & Mark R Gilbert
Review Article: Clinical Investigation
-
Novel clinical trials in neuro-oncology
Aaron G Mammoser, David E Blas-Boria1 & Mark R Gilbert
Review Article: Clinical Investigation